Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | NAAA | Q02083 | 1/20 | 0.36 |
| ▸ | PTPN7 | P35236 | 4/20 | 0.35 |
| ▸ | HMGCR | P04035 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10717466 | 1.00 | TSHR (0.42) | TSHRTHRBNAAAPTPN7HMGCR | |
| SCHEMBL27710723 | 1.00 | TSHR (0.42) | TSHRTHRBNAAAPTPN7HMGCR | |
| SCHEMBL8187522 | 1.00 | TSHR (0.42) | TSHRTHRBNAAAPTPN7HMGCR | |
| SCHEMBL8187524 | 1.00 | TSHR (0.42) | TSHRTHRBNAAAPTPN7HMGCR | |
| SCHEMBL3897707 | 1.00 | TSHR (0.42) | TSHRTHRBNAAAPTPN7HMGCR | |
| SCHEMBL9315797 | 1.00 | TSHR (0.42) | TSHRTHRBNAAAPTPN7HMGCR | |
| SCHEMBL10717470 | 1.00 | TSHR (0.42) | TSHRTHRBNAAAPTPN7HMGCR | |
| SCHEMBL8750140 | 0.97 | — | — | |
| SCHEMBL3899481 | 0.89 | — | — | |
| SCHEMBL23647759 | 0.82 | TSHR (0.44) | TSHRTHRBHMGCRDNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022261956-A1 | FRAGRANCE COMPOUNDS | GIVAUDAN SA (CH) | 2022-12-22 | — | — | WO | claimed |
| WO-2022261956-A1 | FRAGRANCE COMPOUNDS | GIVAUDAN SA (CH) | 2022-12-22 | — | — | WO | disclosed |
| EP-3679020-A1 | CYCLOOLEFIN SUBSTITUTED HETEROAROMATIC COMPOUNDS AND THEIR USE | Hutchison Medipharma Limited (CN) | 2020-07-15 | — | — | EP | disclosed |
| WO-2019047909-A1 | CYCLOOLEFIN SUBSTITUTED HETEROAROMATIC COMPOUNDS AND THEIR USE | HUTCHISON MEDIPHARMA LIMITED (CN) | 2019-03-14 | — | — | WO | disclosed |
| US-7517874-B2 | Substituted imidazo[1,5-a][1,4]diazepines and imidazo[1,5-a]pyrazines as cannabinoid receptor agonists for the treatment of pain | CARA THERAPEUTICS, INC. (US) | 2009-04-14 | — | — | US | disclosed |
| US-20080318935-A1 | SUBSTITUTED IMIDAZOHETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318935-A1 | SUBSTITUTED IMIDAZOHETEROCYCLES | CNR1, CNR2, TRPV1 | TSHR 1095/4885THRB 1718/4885NAAA 898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.